Novo Nordisk Investor Presentation - First Nine Months of 2016

Key development milestones Investor presentation First nine months of 2016 Slide 14 Supplemental application for the SWITCH hypoglycaemia trials submitted for Tresiba® (NN1250) in the US Supplemental applications for the LEADER CV trial submitted for Victoza® (NN2211) in the US and EU FDA extended regulatory review period for IDegLira (NN9068) by three months Complete Response Letter received in the US for faster-acting insulin aspart (NN1218) Oral semaglutide (NN9924) phase 3a trial initiations progress as planned changing diabetes novo nordisk

View entire presentation